Zacks Investment Research cut shares of Natera (NASDAQ:NTRA) from a hold rating to a sell rating in a report released on Thursday morning.
According to Zacks, “Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. “
Several other research analysts also recently commented on the stock. Morgan Stanley lifted their target price on shares of Natera from $21.00 to $41.00 and gave the stock an overweight rating in a research note on Friday, September 28th. Cowen reaffirmed a buy rating and issued a $30.00 target price on shares of Natera in a research note on Friday, November 9th. JPMorgan Chase & Co. started coverage on shares of Natera in a research note on Friday, October 5th. They issued a neutral rating and a $26.00 target price on the stock. BidaskClub raised shares of Natera from a strong sell rating to a sell rating in a research note on Friday, December 7th. Finally, TheStreet downgraded shares of Natera from a c- rating to a d+ rating in a research note on Tuesday, October 9th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $28.25.
Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, November 8th. The medical research company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.03). Natera had a negative return on equity of 2,569.52% and a negative net margin of 58.00%. The firm had revenue of $65.30 million during the quarter, compared to analysts’ expectations of $66.42 million. During the same period in the previous year, the firm earned ($0.51) earnings per share. The firm’s quarterly revenue was up 16.8% compared to the same quarter last year. Equities research analysts anticipate that Natera will post -2.15 earnings per share for the current year.
In other Natera news, insider Jonathan Sheena sold 166,667 shares of the business’s stock in a transaction on Tuesday, October 16th. The shares were sold at an average price of $20.66, for a total transaction of $3,443,340.22. Following the transaction, the insider now directly owns 372,583 shares of the company’s stock, valued at approximately $7,697,564.78. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last three months, insiders have sold 168,188 shares of company stock worth $3,462,185. Insiders own 13.18% of the company’s stock.
Institutional investors have recently modified their holdings of the business. Jennison Associates LLC grew its position in shares of Natera by 39.1% in the 3rd quarter. Jennison Associates LLC now owns 3,641,848 shares of the medical research company’s stock worth $87,186,000 after buying an additional 1,024,225 shares during the period. Vanguard Group Inc. boosted its stake in Natera by 28.9% in the 3rd quarter. Vanguard Group Inc. now owns 3,612,860 shares of the medical research company’s stock worth $86,493,000 after purchasing an additional 808,976 shares in the last quarter. Vanguard Group Inc boosted its stake in Natera by 28.9% in the 3rd quarter. Vanguard Group Inc now owns 3,612,860 shares of the medical research company’s stock worth $86,493,000 after purchasing an additional 808,976 shares in the last quarter. BlackRock Inc. boosted its stake in Natera by 33.5% in the 3rd quarter. BlackRock Inc. now owns 2,785,208 shares of the medical research company’s stock worth $66,679,000 after purchasing an additional 698,379 shares in the last quarter. Finally, FMR LLC bought a new position in Natera in the 3rd quarter worth about $59,599,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Read More: How Do Front-End Loads Impact an Investment?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.